Coveted drivers of innovation: BB Biotech’s Koller asks what lies ahead for M&A activity in the biotech sector?

by | Jun 28, 2022

Share this article

Facebook Open Graph

Written by Dr Daniel Koller, Head PM at BB Biotech

The driving force for many new therapeutic approaches for drugs, yet with low stock market valuations – the biotech industry is going through a paradoxical development phase. This in turn is bringing it back on the radar of big pharma players with an eye for a takeover.

Viewed in fundamental terms, the biotech industry has never looked so well-positioned. According to a study published by the IQVIA Institute for Human Data Science, 65 percent all clinical studies underway in 2021 were conducted by smaller biotech companies, which IQVIA itself describes as «emerging». These are defined as companies with annual sales of below USD 500 million that invest less than USD 200 million annually in their research and development pipeline.

A key difference in the current situation compared to the past is the financial strength of today’s biotechs. An increasing number of companies have sufficient liquid funds to drive forward the development of their clinical candidates through to market maturity under their own steam. In other words, they are moving away from the former dependency on development and marketing partnerships with the pharma industry.


A clear indicator of this is another statistical finding of the above-mentioned IQVIA study: In 2021, “emerging pharma” companies submitted their own market approval applications for 76% of their products. Another plus point is that the biotech sector has become the pioneering force in the development of numerous new approaches such as gene therapies, cell-based therapies, and immuno-oncology.

What’s more, there are plenty of signs that these companies are delivering the necessary price-driving news flow – a large number of clinical study results and approval decisions are expected this year, above all in the fields of cancer medicine, neurology and genetic disorders.

Moreover, the pipeline looks very healthy, as the number of patients enrolled in studies is once again higher than it was prior to the coronavirus pandemic. The number of new study applications submitted to the US supervisory agency (Food and Drug Administration, FDA) has also risen further.


At the same time, the pressure is rising on pharma multinationals to generate new growth drivers. The majority of these companies have strategically repositioned themselves over the last decade by focusing their new drug development operations on just a few therapeutic fields.

The innovative power of Big Pharma continues to be evident, with industry giants such as Roche and Bristol-Myers Squibb concentrating on cancer medicine and the likes of Novo Nordisk and Eli Lilly specializing in diabetes treatment. Nonetheless, the pharma industry will have to come up with solutions over the coming years in order to avoid a slump in revenues: according to the FDA, blockbuster drugs with total sales of more than USD 250 billion will lose their patent protection over the coming decade.

Following two relatively quiet years, it looks as if the current market environment is ripe for a surge in takeover deals. At first glance it seems strange that the valuations of most biotech stocks have fallen sharply over the last 12 months. The main reason for this has been – and remains – the decision by many investors to shun growth stocks as part of sector rotation.


At a time of rising inflation and with a potential recession on the horizon, the financial markets have been selling off unprofitable biotech companies that have yet to bring a product to market but at the same have a capital-intensive development pipeline. For these companies, future earnings expectations are being downgraded due to the higher discount rates being applied against a backdrop of rising interest rates. The price targets of analysts are therefore being reined in.

The announcement of Pfizer’s takeover of Biohaven for USD 11.6 billion at the end of May could trigger a spate of further acquisitions this year. The fact that the pharma giant felt the need to offer Biohaven shareholders a premium of 80% on its market share price prior to the announcement of the acquisition once again makes it clear that potential acquirers are prepared to reach deep in their pockets for the right targets – i.e. pioneering technology and market mature products with significant sales potential.

Pharma companies can be expected to focus above all on biotech firms that have received – or are about to receive – market approval for their initial products based on ground-breaking technologies. Among other things, this includes gene editing, where specific faulty gene segments in DNA strands are cut out and modified.

Genes can be added, removed or disconnected with this technology, which has the potential to deliver complete and lasting solutions to various genetic disorders. In the second half of this year, CRISPR Therapeutics and Vertex Pharma will unveil the first approval relevant data in gene editing for the treatment of two genetically induced blood cell formation disorders.

As the treatment costs of this as yet untreatable condition are very high, CRISPR and Vertex would appear to have very high price setting power. It is perfectly conceivable that Vertex, which is already a profitable biotech heavyweight, will attract a takeover offer given that its future potential revenues could run into billions of dollars.

RNA-based therapies such as SiRNA and AOs (antisense oligonucleotides), which have received market approval for drugs in connection with niche indications, represent another commercially attractive area for prospective corporate buyers. Alnylam and Ionis Pharma are two good examples of companies in this area that look to have takeover appeal in light of their first product authorizations and mature technology platforms. In the field of oncology, this is even more true of biotechs that play a pioneering role in the area of immuno-oncology – particularly if they possess products capable of activating the body’s immune defences against tumour cells even better than combination therapies.

By contrast, for small biotech companies with promising technologies but as yet no active agents capable of demonstrating clinical effectiveness, there is still a huge discrepancy between the amount companies believe they are worth for takeover purposes and the price buyers are willing to pay.

The equities of these  companies have suffered the greatest price declines since 2021, and their corporate value has decreased accordingly. In order to secure financing for their most important clinical projects, these companies will have to enter into traditional development partnerships with Big Pharma which involve upfront payments and performance-linked milestone payments. If they turn out to be successful, these partnerships could then lead to takeover offers.

Share this article

Related articles

IFAM 127 | Not if, but when | April 2024

IFAM 127 | Not if, but when | April 2024

Not if, but when… Spring finally seems to have arrived! Since our last edition, we have had the Spring Budget and the Bank of England (BoE) rate announcement to name but a few important landmarks. This has kept us, like all of you I am sure, quite busy over the last...

Sign up to the IFA Magazine Newsletter

Trending articles

IFA Talk logo

IFA Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.

IFA Talk Podcast - listen to the latest episode